Home » Newsletters » BioWorld Science

BioWorld Science

July 28, 2005

View Archived Issues

NB-001 successfully completes phase II study in herpes labialis

CRADA for antiviral testing of Tarvacin

SC-236 attenuates colon tumor activity associated with cigarette smoking

First dual modulator of PGI2 and TXA2 shows promise as an antithrombotic agent

New class of intestinal Pi absorption inhibitor

Japanese Committee for Usage of Unapproved Drugs rules on Chugai drugs

Nonapprovable letter for Namenda for mild Alzheimer's disease

Vernalis completes acquisition of Ionix

Acambis' C. difficile vaccine begins phase I study

Phase III study of MyVax Personalized Immunotherapy cleared to continue

Tapestry to focus on development of TPI-287

U.K. phase I study of Reolysin begins enrollment

Ozarelix begins U.S. phase I/II trial for hormone-dependent prostate cancer

Adacel vaccine now available in U.S.

Novacea and Pierre Fabre partner on oral vinorelbine

Recent patents cover novel treatments for cognitive disorders

Trifunctional bispecific antibodies show promise in the treatment of cancer

Zegerid Chewable Tablets NDA accepted for filing

Blockade of melanocortin-4 receptors increases the potency of morphine

Novel anti-HIV agents reported by Panacos

NDA for indiplon tablets accepted for review

(-)-Gossypol induces apoptosis in cisplatin-resistant head and neck cancer cells

Salagen approved in Japan

Ruboxistaurin reduces vision loss risk in patients with diabetic retinopathy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 3, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...